Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone
by
Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H.
Department of Psychiatry,
Psychopharmacology, University of Pennsylvania, Philadelphia.
Arch Gen Psychiatry 1988 May;45(5):444-50

ABSTRACT

Risk of withdrawal was investigated in a prospective, double-blind comparison of clorazepate dipotassium, a benzodiazepine with a long half-life, and the nonbenzodiazepine buspirone hydrochloride in the long-term treatment of anxious outpatients. Patients were treated with therapeutic doses of clorazepate dipotassium (15 to 60 mg/d) or buspirone hydrochloride (10 to 40 mg/d) for six continuous months before their tranquilizer therapy was blindly and abruptly stopped. There was a significant increase in symptom severity consistent with a withdrawal reaction for the clorazepate group but not the buspirone group. For the clorazepate group, there was a suggestion that previous discontinuous exposure to benzodiazepines might sensitize patients to subsequent withdrawal effects. For the buspirone group, a higher dropout rate raised questions about patient satisfaction with therapy in this rather chronically anxious population.

OCD
SSRIs
Buspirone
Alprazolam
Temazepam
Benzo choices
Benzodiazepines
Future anxiolytics
Clorazepate v lorazepam
Buspirone and 5-HT1a receptors

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family